Register
Login:
Share:
Email Facebook Twitter


Exclusive: Hayden Locke, CEO Emmerson plc, a low cost high margin potash investment
Richard Slape, Oil consultant - Avoiding Losers and Picking Winners, his personal strategy


N4 Pharma Plc Share Chat (N4P)



Share Price: 7.15Bid: 7.00Ask: 7.30Change: 0.00 (0.00%)No Movement on N4 Pharma Plc
Spread: 0.30Spread as %: 4.29%Open: 7.15High: 0.00Low: 0.00Yesterday’s Close: 7.15


Share Discussion for N4 Pharma Plc


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

Vander
Posts: 375
Opinion:No Opinion
Price:7.15
RE: Helloooo
Today 11:20
We are looking for steady progress. We now have an internal programme of research lead by dr Jansen and funded by part of their £1m placing. Eu ncl is horizon 2020 funded and UoA costs only £30k (university subsidised)

They are testing multiple pDNA antigens other then OVA, mRNA and peptide/ small molecule delivery with results in H2. N4p are focused on intra dermal vaccines for infectious diseases initially but the high profits are in IO.

Nuvec needs to more developed before it can attract partners- hopefully by the end of the year? They must be willing to take a risk on an alternative class of nanoparticle- various universities are testing them- in Tokyo, shanghai, Milan, Mainz, California
 
waccybaccy
Posts: 128
Opinion:No Opinion
Price:7.15
RE: Helloooo
Sat 00:49
I don't think we are due any big surprises soon - surely they would come during clinical trials? Hopefully Adelaide will report back saying it works as already tested and is suitable for a "proper" (not sure which phase... I lose track) clinical trial. This would be a nice positive to keep sentiment good.
Purdey
Posts: 927
Opinion:No Opinion
Price:7.15
RE: RNS
Fri 17:04
Thank you
mazik
Posts: 2,169
Opinion:No Opinion
Price:7.15
RE: RNS
Fri 16:34
Purdey think about it there is a deal in front of us :-) IMO....Shirley has explained it well
Purdey
Posts: 927
Opinion:No Opinion
Price:7.15
RE: RNS
Fri 13:14
Why's he done it I wonder?
bongabob
Posts: 1,621
Opinion:No Opinion
Price:7.15
Helloooo
Fri 11:20
Tumbleweed blowing through here at the moment.
News to drop any time i personally am hoping for a quick top up before the next update.
Q1 coming to a close, big discounts to the placing for those with a little nerve and enjoy the risk factor.
Eerily quiet, best time to buy ?
Surely the downside to upside from here is pretty limited.
Good luck all its been a very slow start to the year but im sure we shall gather momentum as the year goes on.
Record high to be broken by Crimble ! 38p for starters, ta Santa in advance.
Thats my ramptastic post of the Day, Moff to walk the Hounds make some Cheese n Onion Pasties.
gla
Shirley23
Posts: 150
Opinion:No Opinion
Price:7.15
RE: RNS
Fri 08:26
A quick search on the FCA register will tell you this is kind of true.

He works for first equity. He has transferred them from personal holdings to company holdings probably under a discretionary licence. If I recall he even mentioned on twitter he doing this.
djwall1s
Posts: 2,805
Opinion:No Opinion
Price:7.15
...
Thu 11:34
...and there's good chance certain people here masquerade as the equally irritating anti, holdmybeer, on Twitter and other annoying aliases on ADVFN.

Come on, knock it off, you're all as bad with your ramper and deramper accounts, fighting each other in lumps. Nobody needs any of this bs.
bidnolid
Posts: 991
Opinion:No Opinion
Price:7.15
RE: RNS
Thu 11:16
It's a long story, but a user on here 'hughwilson' used to post as hughwilson232 on twitter. He deleted that account because it contained too much misinformation .. he now posts as john edwards, tankerton, james taylor and fido to name a few. Bit of an odd chap to say the least..
Purdey
Posts: 927
Opinion:No Opinion
Price:7.15
RE: RNS
Thu 09:31
What's his twitter username? hughfarrierwilson page doesn't exist on Twitter.
bidnolid
Posts: 991
Opinion:No Opinion
Price:7.15
RE: RNS
Wed 16:16
Yes that source is hughfarrierwilson on twitter.. He posted that on Feb 28th so technically insider info. He removed the tweet but only after someone pointed out that Myles might not be that impressed at the info being made public..
ccsx
Posts: 131
Opinion:No Opinion
Price:7.15
RE: RNS
Wed 15:48
Believe this if you will (from a doubtful source)……

"The transfer of a portion of Myles shares was to family member investment funds which Myles controls. In total Myles now controls 5.13% of the company."
csnfan
Posts: 124
Opinion:No Opinion
Price:7.15
RE: RNS
Wed 15:44
No not him and of course averaging down not up hence confidence in the potential.
mazik
Posts: 2,169
Opinion:No Opinion
Price:7.05
RE: RNS
Wed 12:43
I agree its positive First Equity have bought the stake from M Mc, this should go up...however it gives us a chance to top up..imo
Humbogumbo
Posts: 399
Opinion:No Opinion
Price:7.05
RE: RNS
Wed 12:28
to someone else he may also know....averaging up ?
bidnolid
Posts: 991
Opinion:No Opinion
Price:7.05
RE: RNS
Wed 12:08
There is a 250k sell on NEX immediately after the RNS at below the bid. Was that him selling them at a loss?
csnfan
Posts: 124
Opinion:No Opinion
Price:7.05
RE: RNS
Wed 11:27
Yes everybody - still here despite not posting for a long time. Surely the SP should have gone shooting up with this news not down. First Equity are a wealth management company so would not have considered buying these shares lightly.
By the way regarding the speculation about news on the 250000 buy last Friday. I know the person who did that and it was a share price averaging exercise based on his already large holding. This shows confidence that this share still has has potential
ccsx
Posts: 131
Opinion:No Opinion
Price:7.05
RE: RNS
Wed 10:05
First Equity Limited buy 3,500,000 shares from Myles McNulty.
FeverClucker
Posts: 695
Opinion:No Opinion
Price:7.35
RNS
Wed 09:42
Holdings-interesting....
waccybaccy
Posts: 128
Opinion:No Opinion
Price:7.25
RE: N4P
17 Mar '19
Indeed, 2 weeks to go.
Vander
Posts: 375
Opinion:No Opinion
Price:7.25
RE: alnylam envision study
17 Mar '19
It’s positive for the field that another RNAi product is likely to get fda approval- this time for acute hepatic porphyria

Overall more evidence that the technology can be made to work

The cause of the side effects of givosiran are not clear- Alnylam suggest it was the AHP itself. Could it relate to NPLs?

Nuvec is reliant on the rna/dna story succeeding, and achieving a niche within that. If these companies achieve licences for multiple indications and multiple routes of administration, it is possible they will wish to diversify their means of delivery
zebbo
Posts: 1,182
Opinion:No Opinion
Price:7.25
RE: alnylam envision study
17 Mar '19
Not sure if its good or bad news
Vander
Posts: 375
Opinion:No Opinion
Price:7.25
alnylam envision study
16 Mar '19
Envision phase 3 study: overall good-positive efficacy, but some safety concerns- liver and renal

http://www.evaluate.com/vantage/articles/news/trial-results/alnylam-touts-givosiran-win-despite-toxicity-fears
Matts241
Posts: 6
Opinion:No Opinion
Price:7.25
Chunky buy
15 Mar '19
250,000 buy at end of day. News coming on Monday???
Bckttsim
Posts: 2,071
Opinion:No Opinion
Price:7.20
N4P
15 Mar '19
Up 3% on NEX
Hiding the buys !




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.